Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators. Regulators being skeptical about Lykos' medicine could be bad for Compass.

Compass is a market leader in real estate brokerage, showing strong growth and cost control despite a sluggish market. I expect the real estate market to improve as the Federal Reserve is likely to ...

A downtrend has been apparent in Compass Therapeutics, Inc. (CMPX) lately with too much selling pressure. The stock has declined 23.5% over the past four weeks. However, given the fact that it is now ...

When it comes to Compass, the whales are buying the dip. Several dozen institutional investors have taken up positions in the residential brokerage as of the end of the second quarter, according to an ...

FTSE 100 contract caterer Compass Group (LSE:CPG) absolutely dominates its industry, but the stock’s faltered this year. So should I buy the dip, or is this a sign of things to come? Itâ s fair to say ...

Widest interval of low-grade mineralization was 19 m at 0.84 g/t Au (from 170 m) Mineralization remains open at depth The Company is considering a metallurgical sample test program of high-grade, near ...

If you can do the mental work to separate your sentiment about a stock from its recent price action, buying the dip in a recently dented winner can be a profitable investing strategy. Of course, it's ...